The US FDA has awarded Kazia Therapeutics (ASX:KZA) a designation for its treatment for rare brain cancer in children. The designation means that the clinical trial sponsor could be up to receive a priority review voucher if the drug is initially approved for the target disease. It also grants the holder a fast-track six-month review of the drug application. Shares are trading 2.4 per cent higher at $0.64.
Watch the new story here.